Cara Therapeutics | CARA - Net Income

Stock Price
3.17
Daily Change
-0.16 -4.80%
Monthly
-19.95%
Yearly
-79.48%
Q1 Forecast
3.19

Cara Therapeutics reported $-4.91M in Net Income for its fiscal quarter ending in March of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Alterity Therapeutics Limited AUD -5.77M 2.26M Jun/2023
Assertio Holdings USD -2.92M 753K Sep/2024
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Cassava Sciences USD -12.54M 1.73M Dec/2025
Chugai Pharma JPY 128.41B 17.2B Dec/2025
Cipla INR 6.76B 6.75B Dec/2025
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD 56.84M 63.82M Dec/2025
CSL USD 401M 96.5M Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
J&J USD 5.12B 36M Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pacira USD 1.64M 3.8M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
RedHill Biopharma USD -1.54M 0 Jun/2024
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024